AstraZeneca PE Ratio 2006-2019 | AZN

Current and historical p/e ratio for AstraZeneca (AZN) from 2006 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. AstraZeneca PE ratio as of February 28, 2020 is 25.46.
AstraZeneca PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2020-02-28 43.80 53.41
2019-09-30 44.57 $0.82 54.35
2019-06-30 41.28 $0.87 47.45
2019-03-31 40.43 $0.96 42.11
2018-12-31 37.98 $0.85 44.68
2018-09-30 39.57 $0.96 41.22
2018-06-30 34.72 $1.06 32.75
2018-03-31 34.58 $1.11 31.15
2017-12-31 33.38 $1.19 28.05
2017-09-30 32.59 $1.40 23.28
2017-06-30 32.30 $1.53 21.11
2017-03-31 29.50 $1.34 22.02
2016-12-31 25.06 $1.39 18.03
2016-09-30 30.14 $0.98 30.76
2016-06-30 27.32 $0.88 31.05
2016-03-31 25.49 $1.16 21.97
2015-12-31 29.79 $1.12 26.59
2015-09-30 27.92 $0.68 41.36
2015-06-30 27.58 $0.48 58.06
2015-03-31 29.62 $0.51 58.08
2014-12-31 29.63 $0.49 60.47
2014-09-30 30.08 $0.41 74.26
2014-06-30 30.88 $0.80 38.60
2014-03-31 26.96 $0.82 33.08
2013-12-31 23.98 $1.02 23.51
2013-09-30 20.97 $1.84 11.40
2013-06-30 18.77 $1.95 9.62
2013-03-31 19.83 $2.26 8.79
2012-12-31 18.01 $2.49 7.23
2012-09-30 18.23 $2.46 7.41
2012-06-30 16.73 $3.14 5.34
2012-03-31 16.63 $3.26 5.10
2011-12-31 16.59 $3.66 4.54
2011-09-30 15.90 $3.65 4.36
2011-06-30 17.61 $2.90 6.07
2011-03-31 16.22 $2.87 5.66
2010-12-31 15.64 $2.79 5.61
2010-09-30 17.16 $2.75 6.24
2010-06-30 15.74 $2.95 5.34
2010-03-31 14.93 $2.81 5.31
2009-12-31 15.10 $2.60 5.82
2009-09-30 14.46 $2.49 5.81
2009-06-30 14.02 $2.36 5.95
2009-03-31 11.26 $2.32 4.85
2008-12-31 12.54 $2.10 5.98
2008-09-30 13.41 $2.10 6.40
2008-06-30 12.85 $1.96 6.57
2008-03-31 11.48 $1.88 6.12
2007-12-31 12.50 $1.87 6.69
2007-09-30 14.62 $1.91 7.67
2007-06-30 15.46 $1.96 7.91
2007-03-31 15.51 $1.99 7.81
2006-12-31 15.16 $1.93 7.87
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $118.253B $24.384B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $366.542B 16.03
Roche Holding AG (RHHBY) Switzerland $279.316B 0.00
Merck (MRK) United States $198.032B 15.04
Novartis AG (NVS) Switzerland $197.141B 16.42
Pfizer (PFE) United States $188.714B 11.56
Novo Nordisk (NVO) Denmark $140.872B 24.18
AbbVie (ABBV) United States $126.350B 9.55
Eli Lilly (LLY) United States $123.555B 21.39
Sanofi (SNY) France $120.599B 14.33
GlaxoSmithKline (GSK) United Kingdom $103.779B 13.16
Bristol-Myers Squibb (BMY) United States $97.073B 12.76
Bayer (BAYRY) Germany $67.330B 9.70
H Lundbeck (HLUYY) Denmark $6.839B 11.88